Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Alkem Labs was issued drug alerts twice last year -- in June and July -- for its drug Glimekem.
The markets opened firm with tech, bank and pharma scrips making steady gains.
BSE IT index was the biggest sectoral loser, down 1.5% dragged by TCS
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
IT, pharma and FMCG stocks are the top performers in 2013.
The Sensex ended 290 points higher at 29,095 mark and the Nifty gained 94 points to close at 8,806 levels.
Sensex lost ground towards the fag-end on selling in old and new economy stocks, and finally finished with a loss of three points.
The Sensex opened with a negative gap of 19 points at 6,896, but soon touched a high of 6,955 in early deals.
Among other stocks, IT firm Mphasis today reported a 15.30% increase in consolidated net profit at Rs 184.72 crore for the quarter ended September 30, 2015.
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
ITC, Sun Pharma, Cipla and Tata Steel were top gainers on BSE Sensex
The Sensex opened with a positive gap of 11 points at 5,381, it slipped marginally to touch an intra-day low of 5,380.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Pharma shares were the top gainers led by Lupin after the company received EIR from USFDA for its Goa facility
n the broader market, both the BSE Midcap and Smallcap indices, were up 1.2% and 0.7% each.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Infosys, TCS, HUL and Reliance Industries were the top gainers of the day.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The announcement comes a day after the Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The S&P BSE 500 index, which accounts for 94% market capitalisation of BSE listed companies, has gained 45% from its March 24 low. However, out of the BSE 500 index stocks, 225 have underperformed the index by gaining less than the broader index during this period.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The country had the third-largest number of people living with disease.
As record stock market rally continues, the value of shares directly owned by next-generation business leaders at 20 major corporate houses has soared over 18 per cent to Rs 17,000 crore.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Covering-up of short positions ahead of Thursday's expiry of August series in the derivatives segment gave equities a slight push
Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts.
ICICI Bank was the top Sensex gainer after S&P Global Ratings affirmed its 'BBB-' long-term issue ratings on the senior unsecured bonds.
After touching a fresh all-time low against the US dollar on Thursday, the rupee jumped 27 paise to end at 68.46.
The top gainers on the Sensex were Cipla, Bharti Airtel, Maruti Suzuki, Hero Moto & Sesa Sterlite.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Of the 30-share Sensex pack, 22 ended with losses while NTPC ended flat at Rs 127.30.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
